TCDA

Tricida, Inc. [TCDA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TCDA Stock Summary

In the News

TCDA Financial details

Company Rating
-
Market Cap
5.95M
Income
-143.91M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
27 Mar 2023
P/E
-0.07
Forward P/E
-
PEG
0.01
P/S
-
P/B
-0.05
P/C
-
P/FCF
-0.08
Quick Ratio
4.74
Current Ratio
4.87
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.56
EPS next Y
-
EPS next Q
-
EPS this Y
-26.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9.43%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-96%
ROE
80%
ROC
-1.01%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0411-13.85
52W High
-
52W Low
-
RSI
-
Rel Volume
2.47
Avg Volume
12.58M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
MSF.DE
VOO
GOOGL
VTSAX
BRYN.DE
Same Sector
600518.SS
SLS
IMUC
GRTS
NXTMH.HE
Check Those
IAU
DG
MMM.DE
0A39.L
2538.TW
Similar Market Cap
WCW.L
VIAO
FARVX
KTTAW
MYRX

Company Profile

Healthcare Biotechnology
  • Volume Average 12.58M
  • Market Capitalization 5.95M
  • Employee 57
  • CEO Dr. Gerrit Klaerner Ph.D.
  • Headquarters South San Francisco,CA,US
  • IPO Date 2018-06-28
  • Website https://www.tricida.com

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.